Ketamine ER is under clinical development by Douglas Pharmaceuticals and currently in Phase II for Treatment Resistant Depression. According to GlobalData, Phase II drugs for Treatment Resistant Depression have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ketamine ER overview
Ketamine (R-107) is under development for the treatment of refractory major depressive disorder and treatment-resistant depression. The drug candidate is an extended release formulation administered orally. It acts by targeting glutamate ionotropic receptor AMPA type subunit (AMPA). It was also under development for DSM-5 specific phobia.
Douglas Pharmaceuticals overview
Douglas Pharmaceuticals (Douglas) carries out the development and manufacture of nutraceutical and health products. The company offers consumer, prescription and automation products. Its investigational medicinal products comprise R-107, R-131 and R-147. Douglas provides products in various therapeutic areas which include psoriasis, eczema, dermatitis, chicken pox, constipation, laxative, neonatal, hormone regulation, dermatology, cardiovascular and measles, among others. The company also offers contract manufacturing and laboratory services. It markets its consumer products under various brands which include 3M Futuro, Altrix Range, Avene, Bio Oil, Puria and Resolve, among others. Douglas collaborates with scientific researchers and external medical experts to advance clinical research. It operates in New Zealand, Fiji and the US. Douglas is headquartered in Auckland City, Auckland, New Zealand.
For a complete picture of Ketamine ER’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - Ketamine Er in Treatment Resistant Depression
Premium Insights
The gold standard of business intelligence.
